These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30417131)

  • 21. DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer.
    Vijai M; Baba M; Ramalingam S; Thiyagaraj A
    Oncol Lett; 2021 Dec; 22(6):850. PubMed ID: 34733368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer.
    Sarkar S; O'Connell MR; Okugawa Y; Lee BS; Toiyama Y; Kusunoki M; Daboval RD; Goel A; Singh P
    Mol Cancer Res; 2017 Dec; 15(12):1678-1691. PubMed ID: 28851816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of DCLK1 in oncogenic signaling (Review).
    Lu Q; Feng H; Chen H; Weygant N; Du J; Yan Z; Cao Z
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36148883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells.
    Li L; Mei H; Commey ANA
    Cancer Gene Ther; 2020 Sep; 27(9):691-701. PubMed ID: 31636360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1.
    Patel O; Roy MJ; Kropp A; Hardy JM; Dai W; Lucet IS
    Commun Biol; 2021 Sep; 4(1):1105. PubMed ID: 34545159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
    Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
    Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doublecortin-like kinase 1-positive enterocyte - a new cell type in human intestine.
    Leppänen J; Helminen O; Huhta H; Kauppila JH; Miinalainen I; Ronkainen VP; Saarnio J; Lehenkari PP; Karttunen TJ
    APMIS; 2016 Nov; 124(11):958-965. PubMed ID: 27677532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.
    Liu J; Feng Y; Zeng X; He M; Gong Y; Liu Y
    J Cell Mol Med; 2021 Feb; 25(4):1911-1926. PubMed ID: 33350586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
    Wu X; Ruan Y; Jiang H; Xu C
    Int J Biochem Cell Biol; 2017 Apr; 85():66-74. PubMed ID: 28161486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
    Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
    Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.
    Chhetri D; Vengadassalapathy S; Venkadassalapathy S; Balachandran V; Umapathy VR; Veeraraghavan VP; Jayaraman S; Patil S; Iyaswamy A; Palaniyandi K; Gnanasampanthapandian D
    Front Mol Biosci; 2022; 9():965730. PubMed ID: 36250024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profile of Dclk1
    Yamaga Y; Fukuda A; Nakanishi Y; Goto N; Matsumoto Y; Yoshioka T; Maruno T; Chiba T; Seno H
    Dig Liver Dis; 2018 Dec; 50(12):1353-1361. PubMed ID: 30001952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
    Wang J; Wang S; Zhou J; Qian Q
    Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic significance of doublecortin-like kinase 1 in patients with hepatocellular carcinoma.
    Fan M; Qian N; Dai G
    Oncol Lett; 2017 Dec; 14(6):7529-7537. PubMed ID: 29344199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
    Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
    Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
    Gao T; Wang M; Xu L; Wen T; Liu J; An G
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments.
    Wu X; Qu D; Weygant N; Peng J; Houchen CW
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.